US WorldMeds, LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From US WorldMeds, LLC
Keeping Track: US FDA Clears Opioid Seglentis And Anti-Opioid Zimhi; CRLs For Revance, United; Delay For UCB
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
Japan's latest batch of new drug approvals includes the country's second CAR-T therapy, along with multiple oncology drugs and a novel migraine treatments, which should all reach the market in the next few months following reimbursement price listing.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Sloan Pharma S.a.r.l
- Solstice Neurosciences